IGF2 and ovarian carcinoma: This finding aligns with established clinical evidence in ovarian cancer: elevated serum HGF levels decrease upon chemotherapy [19], and tumor tissues exhibit a three-fold increase in IGF2 expression compared to normal tissue, correlating with poorer prognosis [20].